Tumour cell uptake of lactosaminated and intact N-succinylchitosans and antitumour effects of conjugates with mitomycin C

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2771-2776

  Kato, Yoshinori ^a   Onishi, Hiraku ^a   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

AH130; Antitumour effects; Lactosaminated N succinylchitosan; M5076; MH134; N succinyl chitosan

Indexed keywords

CHITOSAN DERIVATIVE; DRUG CARRIER; LACTOSE MODIFIED N SUCCINYLCHITOSAN; MITOMYCIN C; N SUCCINYLCHITOSAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG UPTAKE; FEMALE; FLUORESCENCE MICROSCOPY; HEPATOMA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHITIN; CHITOSAN; DRUG CARRIERS; FEMALE; LACTOSE; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MITOMYCIN; RATS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036766002     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Felt O, Buri P and Gurny R: Chitosan: A unique polysaccharide for drug delivery. Drug Dev Ind Pharm 24: 979-993, 1998.
2. Song Y, Onishi H and Nagai T: Conjugate of mitomycin C with N-succinyl-chitosan: In vitro drug release properties, toxicity and antitumour activity. Int J Pharm 98: 121-130, 1993.
3. Kato Y, Onishi H and Machida Y: Evaluation of N-succinyl-chitosan as a systemic long-circulating polymer. Biomaterials 21: 1579-1585, 2000.
4. Kato Y, Onishi H and Machida Y: A novel water-soluble N-succinylchitosan-mitomycin C conjugate prepared by direct carbodiimide coupling: physicochemical properties, Anti-cancer characteristics and systemic retention. STP Pharma Sci 10: 133-142, 2000.
5. Kato Y, Onishi H and Machida Y: Biological fate of highly-succinylated N-succinyl-chitosan and Anti-cancer characteristics of its water-soluble conjugate with mitomycin C at i.v. and i.p. administration into tumour-bearing mice. Biol Pharm Bull 23: 1497-1503, 2000.
6. Kato Y, Onishi H and Machida Y: Efficacy of lactosaminated and intact N-succinyl-chitosan-mitomycin C conjugates against M5076 liver metastatic cancer. J Pharm Pharmacol 54: 529-537, 2002.
7. Kato Y, Onishi H and Machida Y: Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Contr Rel 70: 295-307, 2001.
8. Kato Y, Onishi H and Machida Y: Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis. Int J Pharm 226: 93-106, 2001,
9. Tessitore L, Bonelli G and Baccino FM: Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. Biochem J 241: 153-159, 1987.
10. Hisano G, Yata K and Tsubura E: Antitumour effect of levamisole. Jpn J Cancer Chemother 9: 1119-1120, 1982.
11. Hart IR, Talmadge JE and Fidler IJ: Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res 41: 1281-1287, 1981.
12. Schwartz AL, Fridovich SE, Knowles BB and Lodish HF: Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. J Biol Chem 256: 8878-8881, 1981.
13. Virgolini I, Muller C, Klepetko W, Angelberger P, Bergmann H, O'Grady J and Sinzinger H: Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand. Br J Cancer 61: 937-941, 1990.
14. Nagy JA, Herzberg KT, Masse EM, Zientara GP and Dvorak HF: Exchange of macromolecules between plasma and peritoneal cavity in ascites tumour-bearing, normal, and serotonin-injected mice. Cancer Res 49: 5448-5458, 1989.